Capsule-in-Capsule Technology - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Capsule-in-Capsule Technology
The author outlines how to choose carriers and capsule shells according to dosage requirements and intended use. This article is part of a special Drug Delivery issue.

Pharmaceutical Technology
pp. s26-s29

This article is part of a special issue on Drug Delivery.

Liquid-filled hard-capsule technology is well-established for formulation and manufacture (1). In addition to being a convenient product format, it is well recognized as offering a wide range of applications, including for use in compounds with low bioavailability or with low-dose uniformity issues. Liquid-filled hard capsules can provide products with various release profiles and may be used to overcome stability concerns such as moisture uptake. Capsule-in-capsule formats represent a significant further development in the product type. In this format, a formulated capsule (i.e., liquid-filled or dry-filled) is nested in an outer liquid-filled capsule. Each capsule achieves a particular formulation aim (e.g., prompt or controlled release). This article will describe formulation approaches and provide examples of in vitro investigations of a capsule-in-capsule system that enables the presentation of multiphase or multidrug formulations in a single dosage unit.

Formulation aims and carrier selection

Figure 1 suggests a range of possible formulation aims that capsule-in-capsule technology may achieve. This drug-delivery system has beneficial flexibility. The formulation aims for each component capsule may be achieved by selecting the carrier suited to the particular delivery goal (e.g., a prompt or slow-release profile). Available carriers include the following options:
  • Nonaqueous fluid, possibly thickened with a thixotropic agent (e.g., colloidal silicone dioxide)
  • Thermosoftening excipients with various solution characteristics that can be matched to in vivo release requirements
  • Self-emulsifying carriers.

Figure 1: Target areas for the capsule-in-capsule platform. CPD is compound. (FIGURE IS COURTESY OF THE AUTHOR)
The resulting formulations may be nonaqueous solutions, suspensions, semisolid matrices, or microemulsions, all of which are suited to liquid-filled hard capsule formats.

Common suitable nonaqueous fluids include pharmaceutical or nutraceutical oils (e.g., medium-chain triglycerides or soya oil), which are selected according to technical or market needs. Individual materials may require the inclusion of antioxidants or filling under nitrogen to minimize oxidation. Thermosoftening carriers are commonly fully synthetic [e.g., the high-molecular-weight polyethylene glycols (PEGs) or poloxamers], selected according to melting point and viscosity. Thermosoftening carriers also may be semisynthetics such as the macrogolglycerides (e.g., lauroyl, linoleoyl, and caprylocaproyl), selected according to melting point and hydrophilic–lipophilic balance (HLB). Varying carrier HLB values (i.e., 2–14) enable the solubility profile of the active ingredient to be matched to the required release profile. For example, a soluble compound may be formulated with a low-HLB carrier to give a slow-release profile, and a high-HLB material may improve the dissolution rate of a poorly soluble active.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here